NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis $2.58 +0.27 (+11.69%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.31▼$2.6350-Day Range$1.78▼$2.5852-Week Range$1.05▼$2.63Volume405,202 shsAverage Volume211,659 shsMarket Capitalization$161.38 millionP/E RatioN/ADividend YieldN/APrice Target$5.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Corvus Pharmaceuticals alerts: Email Address Corvus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside100.3% Upside$5.17 Price TargetShort InterestHealthy2.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingAcquiring Shares$1.03 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.49) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.34 out of 5 starsMedical Sector337th out of 936 stocksPharmaceutical Preparations Industry156th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCorvus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Corvus Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.00% of the outstanding shares of Corvus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently decreased by 12.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVS. Previous Next 3.6 News and Social Media Coverage News SentimentCorvus Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Corvus Pharmaceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for CRVS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,033,907.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corvus Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($0.49) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corvus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Read More CRVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRVS Stock News HeadlinesJuly 17, 2024 | americanbankingnews.comCorvus Pharmaceuticals (NASDAQ:CRVS) Stock Passes Below 50 Day Moving Average of $2.02May 31, 2024 | investorplace.comThe 2024 Millionaire's Club: 3 Penny Stocks to Buy NowJuly 27, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.May 30, 2024 | globenewswire.comCorvus Pharmaceuticals to Present at the Jefferies Global Health ConferenceMay 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Corvus Pharmaceuticals, Inc. (CRVS) and Encourages Investors to Contact the FirmMay 12, 2024 | finance.yahoo.com13 Penny Stocks with Insider Buying in 2024May 10, 2024 | finance.yahoo.comInsider Spends US$1m Buying More Shares In Corvus PharmaceuticalsMay 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call TranscriptJuly 27, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.May 7, 2024 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comQ1 2024 Corvus Pharmaceuticals Inc Earnings CallMay 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 6, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024May 2, 2024 | globenewswire.comCorvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingApril 24, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (CRVS)April 17, 2024 | finance.yahoo.comHere's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 WeeksApril 9, 2024 | globenewswire.comCorvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisSee More Headlines Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/27/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVS CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$5.17 High Stock Price Target$8.00 Low Stock Price Target$3.50 Potential Upside/Downside+100.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.96% Return on Assets-50.83% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio3.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book3.27Miscellaneous Outstanding Shares62,550,000Free Float42,973,000Market Cap$161.38 million OptionableOptionable Beta1.11 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Richard A. Miller M.D. (Age 73)Co-Founder, President, CEO & Chairman of the Board Comp: $116.31kDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Director Comp: $47kMr. Leiv Lea (Age 70)Chief Financial Officer Comp: $400.21kDr. William Benton Jones Ph.D. (Age 58)Senior Vice President of Pharmaceutical Development Comp: $355.7kDr. James T. Rosenbaum M.D.Senior Vice President of ResearchMr. Jeffrey S. ArcaraChief Business OfficerMore ExecutivesKey CompetitorsOncolytics BiotechNASDAQ:ONCYEnlivex TherapeuticsNASDAQ:ENLVOrgenesisNASDAQ:ORGSAytu BioPharmaNASDAQ:AYTUContineum TherapeuticsNASDAQ:CTNMView All CompetitorsInsiders & InstitutionsTowerview LLCBought 17,500 shares on 7/26/2024Ownership: 0.639%BVF Inc. ILSold 1,009,541 shares on 5/16/2024Ownership: 0.737%Vanguard Group Inc.Bought 142,724 shares on 5/10/2024Ownership: 3.045%Towerview LLCSold 54,373 shares on 5/7/2024Ownership: 0.780%Richard A Md MillerBought 577,634 shares on 5/6/2024Total: $999,306.82 ($1.73/share)View All Insider TransactionsView All Institutional Transactions CRVS Stock Analysis - Frequently Asked Questions How have CRVS shares performed this year? Corvus Pharmaceuticals' stock was trading at $1.76 at the beginning of the year. Since then, CRVS stock has increased by 46.6% and is now trading at $2.58. View the best growth stocks for 2024 here. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) announced its earnings results on Monday, May, 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO? 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend. When did Corvus Pharmaceuticals IPO? Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Top institutional investors of Corvus Pharmaceuticals include Towerview LLC (0.64%). Insiders that own company stock include Richard A Md Miller, William Benton Jones, Leiv Lea, Linda Grais, Orbimed Advisors Llc and Ecor1 Capital, Llc. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN) and SCYNEXIS (SCYX). This page (NASDAQ:CRVS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRVS Stock Alerts